PubMed Health⌕ Search

Biomedical subjects

G D Wilner

Publications and source records attributed to G D Wilner.

At least 37 records · Page 2Linked to original sources
PubMed1984

Localization of a chemotactic domain in human thrombin.

The cyanogen bromide fragment CB67-129 of human prethrombin 1, corresponding to residues 54-116 of the thrombin B chain, is a potent chemotaxin for human peripheral blood monocytes and the murine macrophage like cell line, J774. Both of these cell types have been shown to respond chemotactically to alpha-thrombin and iPr2P-alpha-thrombin. Effective concentrations for stimulating directed cell movement with the fragment vary from 10(-11) to 10(-7) M. Moreover, CB67-129 and its parent protein compete for the same chemotactic receptor site. Fragment CB67-129, representing residues 54-116 of the human thrombin B chain sequence, contains a nine-residue insertion ("loop B") that is absent in homologous sequences derived from the closely related proteases chymotrypsin and trypsin. Unlike iPr2P-alpha-thrombin, iPr2P derivatives of these latter enzymes possess little or no chemotactic activity, suggesting a relationship between the insertion sequence and thrombin chemotactic activity. The loop B sequence is unique insofar as it contains all of the carbohydrate moieties known to reside in alpha-thrombin. However, chemotactic activity is only minimally reduced subsequent to hydrolysis by both neuraminidase and beta-galactosidase, indicating that receptor recognition and stimulated cell movement are mainly a function of structure of the cyanogen bromide derived fragment rather than of asparagine-linked carbohydrates.

Amino Acid Sequence↗
PubMed1984

Lack of elevation of platelet factor IV in plasma from patients with myocardial infarction.

Platelet factor IV and beta-thromboglobulin are protein constituents of platelet granules. Elevated levels of these proteins in plasma have been used as sensitive indicators of platelet degranulation. Clearance of platelet factor IV is much faster than that of beta-thromboglobulin after release of the proteins in vivo. Although increases of platelet factor IV have been observed in patients with infarction, the implication that they reflect pathogenetic phenomena such as coronary thrombosis has not been assessed explicitly. Accordingly, plasma samples obtained serially from 52 patients with acute myocardial infarction under rigorous conditions verified to minimize platelet degranulation in vitro were evaluated prospectively. Correlative studies were performed to detect left ventricular mural thrombus, and coronary thrombosis was assessed independently in selected patients with indium-111 platelet scintigraphy. Platelet factor IV was normal at the time of admission in patients with infarction, averaging 6.3 +/- 3.3 ng/ml, similar to values in 44 other patients with chest pain without subsequent infarction (5.7 +/- 2.7 ng/ml) and in 25 normal subjects (4.3 +/- 1.6 ng/ml). Platelet factor IV generally did not increase during hospitalization in patients with infarction despite recurrent chest pain, development of left ventricular thrombus or documented recurrent infarction. However, platelet factor IV increased consistently after invasive procedures, accounting for 104 of the total of 110 increases due to platelet activation in vivo as reflected by persistence of elevated levels of beta-thromboglobulin. Thus, platelet factor IV values generally remain normal despite acute myocardial infarction. Rare increases that occur reflect platelet degranulation in vitro due to sampling artifact or perturbations of platelets in vivo due to invasive procedures.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1984

Fibrin-mediated vascular injury. Identification of fibrin peptides that mediate endothelial cell retraction.

The deposition of fibrin, a ubiquitous component of acute and chronic inflammatory reactions, has been implicated by a number of recent studies as playing an active role in inflammation. In particular, fibrin deposition has been implicated in the development of tissue edema. As the "gateway" through which intravascular-to-extravascular movement of fluid, nutrients, and cells must pass, the vascular endothelial cells play a crucial regulatory role in this process. In support of this concept, recent studies in this laboratory have demonstrated that endothelial cells retract not only in the presence of fibrin but also in the presence of low molecular weight cleavage products of fibrinogen. It was further shown that this reaction was 1) specific for both vascular and corneal endothelial cells, 2) nontoxic, and 3) completely reversible. The present work examined the physiochemical nature of these endothelial-cell reactive factors. It was demonstrated by the use of enzymatically derived and synthetic fibrinogen peptides, that the active soluble fibrinogen-derived factor was associated with the amino-terminal end of the B chain of fibrinogen. The active factor has been tentatively identified as the B beta peptides, which is a primary plasmin cleavage product of fibrinogen and contains the thrombin-generated fibrinopeptide B. It is thus suggested that soluble, endothelial-cell-reactive peptides are released during both fibrinogenesis and fibrinolysis and, as such, modulate endothelial cell functions in vivo.

Animals↗
PubMed1983

Monocyte chemotaxis: stimulation by specific exosite region in thrombin.

Human alpha-thrombin is a potent chemoattractant for human monocytes, with optimum activity occurring at about 10 nanomoles per liter. A variety of thrombins that were chemically modified to alter procoagulant or esterolytic functions showed a similar optimum activity, but complexes of prothrombin or alpha-thrombin with either antithrombin III or hirudin did not. These findings indicate that the regions in thrombin responsible for monocyte chemotaxis are proximate to those involved in certain protein recognition interactions of alpha-thrombin (for example, hirudin binding) but are distinct from the catalytic site and from certain exosites required for clotting.

Binding Sites↗
PubMed1983

Chemotactic response of monocytes to thrombin.

Human alpha-thrombin, the procoagulant activation product of prothrombin, elicits chemotaxis in human peripheral blood monocytes and several macrophagelike continuous cell lines, most notably J-774.2, but not in human peripheral blood granulocytes. alpha-Thrombin is effective in stimulating cell movement at concentrations ranging from 10(-10) to 10(-6) M but is optimally active at 10(-8) M. At the latter concentration, the degree of response is equivalent, on a molar basis, to that observed with the peptide formylmethionylleucylphenylalanine, (FMP). In contrast to thrombin, prothrombin produces a minimal chemotactic response in monocytes and J-774.2. Blockade of alpha-thrombin's active center with diisopropylfluorophosphate (DIP-F) or tryptic proteolysis of the procoagulant exosite (i.e., gamma-thrombin) fails to alter chemotactic activity. On the other hand, addition of equimolar amounts of antithrombin III (AT3) to alpha-thrombin reduces thrombin-mediated chemotaxis by 60%, and increased ratios of AT3 to enzyme completely suppress chemotaxis. We conclude that thrombin is a potent monocyte chemotaxin and that the domains in thrombin involved in stimulating cell movement are distinct from the catalytic site and the fibrin recognition exosite. These chemotactic domains appear to be sequestered in prothrombin and in the thrombin-AT3 complex and, as such, are unavailable to the chemotactic receptor on the monocyte cell membrane.

Binding Sites↗
PubMed1983

Proliferating and helper T lymphocytes display distinct fine specificities in response to human fibrinopeptide B.

The fine specificity of T cell responses involved in the generation of help for antibody production and proliferation was examined by using the 14 amino acid peptide human fibrinopeptide B (hFPB, B beta 1-14) and its synthetic peptide homologues B beta 1-14(Lys14), B beta 1-13, and B beta 3-14. Peritoneal exudate or lymph node T cells from C57BL/10 and B10.BR mice immunized with hFPB or its synthetic homologues were used to measure in vitro proliferative responses. T cells from hFPB-immunized B10.BR mice showed specific proliferation to hFPB, but were unresponsive to B beta 1-14(Lys14), B beta 1-13, and B beta 3-14. B10.BR mice immunized with B beta 1-14(Lys14), B beta 1-13, or B beta 3-14 were unresponsive to all peptides tested. T cells from C57BL/10 mice showed no specific proliferation after immunization and challenge with any of the peptide antigens. In contrast to the patterns of T cell proliferation, immunization of both B10.BR and C57BL/10 mice with hFPB, B beta 1-14(Lys14), B beta 1-13, or B beta 3-14 primed for significant helper T cell activity, as assessed by the augmentation of a primary in vitro B cell IgM anti-FITC plaque-forming cell response after culture with B beta 1-1(Lys14)-FITC. Significant peptide-specific helper activity was observed when the FITC moiety was conjugated to the carboxyl terminal lysine (B beta 1-14(Lys14)-FITC) as well as FITC substitution at the amino terminus (FITC-B beta 3-13 or FITC-B beta 3-14). These results suggest that the fine specificity of T cell responses to peptide antigens are different for helper and proliferating T cells and that responsiveness by one T cell subpopulation does not predict the response pattern of other functional subpopulations.

Animals↗
PubMed1983

Functional differentiation in the genetic control of murine T lymphocyte responses to human fibrinopeptide B.

The ability to generate proliferative and helper T lymphocyte responses in mice was compared by using the 14 amino acid peptide, human fibrinopeptide B (hFPB). Lymph node or peritoneal exudate T cells from mice immunized with hFPB were assessed for in vitro proliferation to soluble hFPB as determined by the uptake of 3H-thymidine. The T cell proliferative response to hFPB was found to be under MHC-linked Ir gene control; mice possessing the H-2a,k haplotypes were responders, whereas H-2b,d,q,s mice were nonresponders. The influence of non-H-2 genes on these responses was not investigated, so exclusive regulation by H-2 is provisional. The absence of a detectable lymph node and peritoneal exudate T cell proliferative response persisted in H-2b,d,q,s mice after immunization and boosting with several doses of hFPB. In addition, the capacity to produce a T cell proliferative response was inherited in an autosomal dominant manner and gene(s) controlling responsiveness to hFPB mapped to the I-A subregion of the H-2 complex. To measure peptide-specific helper T cell activity, an in vitro microculture assay in which hFPB-primed lymph node T cells and normal spleen B cells and macrophages were used was developed measuring anti-fluorescein isothiocyanate (FITC) IgM and IgG plaque-forming cell (PFC) responses after culture with FITC-conjugated peptide. Immunization of B10.BR, C57BL/10, B10.D2, and B6AF mice with hFPB primed for significant helper T cell activity as assessed by the ability to augment a primary in vitro IgM response to FITC. The normal B cell IgM responses were completely dependent on hFPB-primed T cells and required that hapten (FITC) and carrier (peptide) be linked. In addition, immunization with FITC-conjugated peptide elicited positive in vivo PFC responses to FITC in B10.BR and C57BL/10 mice, indicating similar genetic control of helper activity in both the intact animals and the in vitro microcultures. Thus, B10.BR mice show both T help and T proliferative responses to hFPB, whereas C57BL/10 mice show only T help and no T proliferative responses. In contrast to B10.BR mice, C3H and CBA mice immunized with hFPB were completely unresponsive when assayed for helper T cell activity in vitro despite their ability to generate positive lymph node T cell proliferative responses. These results indicate responsiveness to hFPB by T helper and proliferating cells is different and is under separate genetic control.

Animals↗
PubMed1983

Receptor-mediated chemotactic response of a macrophage cell line (J774) to thrombin.

Human alpha-thrombin, the procoagulant activation product of prothrombin, elicits chemotaxis in several macrophage-like continuous cell lines, most notably J774. Effective alpha-thrombin concentrations eliciting cell movement range from 10(-10) to 10(-6) M, with the optimal response occurring at about 10(-8) M. At the latter concentration, the response is equivalent, on a molar basis, to that observed with f-Met-Leu-Phe-OH, the positive control used in these experiments. Blockage of alpha-thrombin's active center with diisopropylfluorophosphate or by tryptic proteolysis of the procoagulant exosite (i.e., gamma-thrombin) does not decrease chemotactic activity. However, formation of enzymatically inactive complexes with AT3 or hirudin eliminates chemotactic potency. Competition chemotaxis assays, carried out by comparing the abilities of varying concentrations of test substances placed in the upper compartment of Boyden chambers to inhibit gradient-oriented movement of cells toward a fixed concentration of thrombin in the lower compartment, demonstrate that, although the modified forms of thrombin cross-compete, formylated peptide will not inhibit thrombin's chemotactic effects. Binding studies carried out using 125I-alpha-thrombin on paraformaldehyde-fixed J774 cells show a Kd of approximately 7.5 nM with an estimated 14,100-binding sites/cell. This Kd is in agreement with the optimal chemotactic thrombin dose (approximately 10 nM). On the basis of the competition chemotaxis assays and the radiolabeled thrombin-binding data, it is proposed that unique thrombin-specific chemotactic receptors exist on J774 cell membranes, and that these receptors are distinct from those mediating chemotaxis by agents such as formylated peptides.

Animals↗
PubMed1982

T lymphocyte recognition of peptide antigens: evidence favoring the formation of neoantigenic determinants.

To more precisely define the nature of exogenous antigenic determinants recognized by T cells, the response to fibrinopeptide fragment B beta 7-14 and a peptide of the inverted amino acid sequence of B beta 7-14 was examined. Strain 2 guinea pig T cells immunized with B beta 7-14 showed in vitro proliferative responses with B beta 7-14, but failed to respond to the inverted B beta 7-14 peptide. Moreover, the inverted B beta 7-14 peptide was nonimmunogenic and failed to prime strain 2 T cells for responses to native or inverted B beta 7-14. These results suggest that T cell recognition of peptide antigens involves more than simple interactions with amino acid side chains and that the ordering of the amino acids within the peptide is critical. One interpretation of these results is that T cells exhibit polarity in reading of antigenic determinants and peptides become associated with self in some fashion to form a neoantigenic determinant. To test this possibility, a Gly residue was added to the carboxyl end of B beta 7-14 (B beta 7-15), which is the likely site of attachment to self. It was found that strain 13 guinea pigs, which are totally unresponsive to B beta 7-14, produced T cell responses to B beta 7-15. This observation is consistent with the interpretation that Gly spaces the B beta 7-14 away from self to form an antigenic determinant complementary to strain 13 T cell antigen recognition structures. These results are discussed with respect to several mechanisms for immune response gene control of T cell responses.

Amino Acid Sequence↗
PubMed1981

Fine specificity of genetic regulation of guinea pig T lymphocyte responses to angiotensin II and related peptides.

Guinea pig T lymphocyte responses to the octapeptide antigen angiotensin II (NH(2)-Asp(1)-Arg(2)-Val(3)-Tyr(4)-Ile(5)-His(6)-Pro(7)-Phe(8)-OH; AII) were examined using various synthetic peptide analogues and homologues. Each peptide antigen was assessed for immunogenicity and antigenicity in strain 2 and strain 13 guinea pigs as determined by in vitro T cell proliferative responses. The genetic control of T cell responses to these peptides was found to be highly specific and capable of distinguishing subtle differences in the antigens. For example, strain 2 guinea pigs responded to AII and were low responders to [Val(5)]-AII, whereas strain 13 animals responded to [Val(5)]-AII but not to AII. The genetic control in this case involved the difference of one methyl group between Val(5) and Ile(5). Differences in T cell responsiveness by strain 2 and strain 13 guinea pigs were also observed with analogues involving para substitutions on the phenyl ring of Tyr(4) and of Phe(8). However, the genetic regulation of T cell responses did not seem to be based on a single peptide residue. For example, removal of Asp(1) allowed strain 13 animals to respond to the Ile(5)-containing analogue, but eliminated responsiveness to the Val(5)-containing analogue. Thus, the first and fifth AII residues are both involved in the regulation of strain 13 T cell responses. Substitutions for Tyr(4) and Phe(8) suggested that the same residue may serve to alter the specificity of T cell responses in one strain, and determine responsiveness or unresponsiveness in the other strain. One of the most striking observations is that T cell responsiveness to the various AII analogues and homologues randomly fluctuates between strain 2 and strain 13 guinea pigs, and in general neither strain responds to the same peptide antigens. This suggests that strain 2 and strain 13 T cell responses are rarely directed against the same antigenic determinants, and that the T cell antigen-combining diversity is usually exclusive between these two strains. These results are discussed with respect to the specificity of Ir gene control and the relationship between Ir gene function and antigen recognition by T cells. Note added in proof: More recent experiments using a new lot of [Val(5)]- AII have indicated that [Val(5)]-AII-immune strain 2 T cells show significant stimulation with AII but remain relatively low responders with [Val(5)]-AII, as shown in Table I. The difference in priming for cross-reactivity for AII with the different lots of [Val(5)]-AII is at present unknown.

Angiotensin II↗
PubMed1981

Fibrin Polymerization. 1. Alkylating peptide inhibitors of fibrin polymerization.

A series of analogues relating to the NH2-terminal region of the fibrin alpha chain, i.e., Gly-Pro-Arg-Pro, were prepared by stepwise solid-phase synthesis, and their abilities to inhibit fibrin polymerization and to prolong thrombin-initiated clotting time were evaluated. Among the analogues systematically modified at different positions, replacement of the NH2-terminal three residues of Gly-Pro-Arg-Pro by either chlorambucil, p-nitrophenyl-L-alanine, or p-aminophenyl-L-alanine gave inactive compounds in the thrombin time assay, whereas similar substitution or extension of the COOH terminus produced the highly active analogues Gly-Pro-Arg-Phe(4-NH2), 22%; Gly-Pro-Arg-Pro-Phe(4-NO2), and Gly-Pro-Arg-Pro-Phe(4-NH2), 105%; relative to Gly-Pro-Arg-Pro = 100% in the fibrin polymerization inhibitory assay. As potential photoaffinity labeling probes, analogues containing a nitrophenylalanine residue in position 4 or 5 underwent photolysis under the experimental photoactivation conditions. As a potential alkylating probe, Chl-Pro-Arg-Pro was selectively effective in inhibiting thrombin amidolysis and fibrin polymerization. In the latter assay, Chl-Pro-Arg-Pro was approximately 20 times more potent than Gly-Pro-Arg-Pro in inhibiting fibrin aggregation.

Alkylation↗
PubMed1981

Anti-A antibody transfused with non-group-specific platelets. Serological abnormalities.

In 1979 we identified six patients in blood group A who were given non-group-specific platelets and who had difficulties in pretransfusion testing because of passively acquired antibodies to their own A antigen. In all six, results of earlier pretransfusion testing were unremarkable. Postplatelet transfusion findings consisted of the following: (1) negative result of screening for unexpected antibodies, (2) positive result from direct antiglobulin (Coombs') test, (3) incompatible cross match with group A RBCs, and (4) detection of anti-A antibody in each patient's serum and eluate. No clinical evidence of hemolysis was present in any of the patients. Identification of passively acquired ABO antibodies and selection of compatible blood can be facilitated by (1) accurate review of transfusion history for administration of non-group-specific blood products, (2) testing of eluate against group A, B, and O RBCs, and (3) cross match of patient's sera against group O donor RBCs.

ABO Blood-Group System↗
PubMed1980

Nature of T lymphocyte recognition of macrophage-associated antigens. V. Contribution of individual peptide residues of human fibrinopeptide B to T lymphocyte responses.

Guinea pig T lymphocyte responses to a decapeptide antigen (NH1-Asp5-Ans6-Glu7-Glu8-Gly9-Phe10-Phe11-Ser12-Ala13-Arg14-OH) of human fibrinopeptide B (hFPB) were examined using various synthetic peptide analogues containing single residue substitutions. Each analogue was examined for antigenicity as determined by an in vitro proliferative responses of hFPN-immune strain 2 guinae pig T cells. In addition, both strain 2 and strain 13 animals were immunized with each analogue and immunogenicity assessed by in vitro T cell-proliferative responses with the homologous immunizing analogue and the parent peptide. Replacement of arginine14 with lysine formed an immunogenic analogue which showed no antigenic cross-reactivity with the native peptide in strain 2 T cell responses. In addition, substitution of arginine14 with blocked lysine again produced a unique immunogenic analogue that showed little or no antigenic identity with the intact lysine analogue or the native peptide. In similar fashion, substitution of resideu phenylalanie10 with tyrosine or Phe(4-NO2) created unique immunogenic analogues with little or no antigenic identity to the native peptide with strain 2 T cells. By contrast, replacement of phenylalanine11 with either tyrosine or Phe(4-NO2) resulted in analogues with a total loss of immunogenicity and antigenicity in strain 2 T cell responses. An analogue in which glutamic acid7,8 were replaced with glutamine retained a small degree of antigenicity with hFPB-immune T cells, but T cells from strain 2 animals immunized with the Gln analogue responded only marginally to the Gln analogue while producing good proliferative responses with the native peptide. On the other hand, an analogue in which asparatic acid5 was replaced with asparagine retained most of the antigenic identity with hFPB for strain 2 T cell responses. None of thee analogues were immunogenic for strain 13 guinea pigs. These observations are discussed with respect to the contribution of each substituted residue to T cell respones, mechanism of Ir gene function, and a model for T cell recognition of small peptide antigens.

Amino Acid Sequence↗